Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Bloc PENG en comparaison avec l'infiltration anesthésique (PAI) après une hémiarthroplastie de la hanche

26 septembre 2026 mis à jour par: Yasser S Mostafa, MD, Fayoum University Hospital

L'efficacité analgésique du bloc du groupe nerveux péricapsulaire (PENG) en comparaison avec l'infiltration anesthésique locale périarticulaire (PAI) subissant une hémiarthroplastie de la hanche : une étude contrôlée randomisée

The goal of this intervention study is to compare the analgesic efficacy of pericapsular nerve group (PENG) block versus periarticular anesthetic infiltration (PAI) block in patients undergo hemiarthroplasty after spinal anesthesia .

The main questions it aims to answer are:

which block has more analgesic efficacy. which block has more motor-sparing analgesia.

Researchers will compare optimal motor-sparing analgesia between PENG block and PAI after hemiarthroplasty.

Participants will be divided in two groups :

group receive PENG block and other group receive PAI

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

This study aims to compare the analgesic efficacy of pericapsular nerve group (PENG) block versus periarticular anesthetic infiltration (PAI) block in hemiarthroplasty after spinal anesthesia

PARTICIPANTS AND METHODS:

After approval of the local institutional ethics committee and local institutional review board. Patients who are scheduled for elective hemiarthroplasty and fulfilling the inclusion criteria in Fayoum university hospital starting from October 2024 will be enrolled in this randomized controlled study until fulfilling sample size. A detailed informed consent will be signed by the eligible participants before recruitment.

Inclusion criteria The eligibility criteria included ages from 50 to 90 years, American Society of Anesthesiologists (ASA) physical status I to III, and undergoing bipolar hemiarthroplasty in Fayoum university hospital.

Exclusion criteria Patient refusal, contraindication to spinal anesthesia , clinically significant coagulopathy, infection at the injection site, allergy to local anesthetics, body mass index>35 kg m2 , diabetic or other neuropathies, patients receiving opioids for chronic analgesic therapy

. ANESTHETIC TECHNIQUE Perioperative anesthesia management will be according to our hospital routine protocol. An intravenous cannula will be inserted in the hand and standard monitoring (noninvasive blood pressure, electrocardiography, and pulse oximetry) will be applied . In all patients, spinal anesthesia will be performed in the sitting position. The midline and level of the L3-4 and L4-5 intervertebral spaces will be identified, and spinal anesthesia will be administered using 10 mg of isobaric bupivacaine (2mL of bupivacaine 0.5%) injected using 25-gauge Quincke needle. Patients will be immediately placed in the supine position. Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 minutes after the intrathecal injection., the bipolar hemiarthroplasty will be performed in all patients in nondependent lateral position.

Randomization and blinding Using a computer-generated sequence of random numbers and a sealed, opaque envelope technique, patients will be randomly allocated to receive PENG block or PAI . The randomization list and opaque envelopes will be created by an assistant who will not be involved in patient care.

Performance of PENG blocks and PAI PENG BLOCK will be performed in the operating room, after skin closure, .Patients will be placed in the supine position. The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle .

PIA BLOCK For subjects randomized to PAI , LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% ) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues ( anterior and posterior capsules, gluteus minims and Medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus fumoirs muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe

Statistical analysis and sample size estimation Before conducting the study, G*Power 3.1.9.6 will be utilized to establish the appropriate sample size for equal distribution among the two groups based on data from the study by Bravo et al. who recorded median and range between the same two groups for numeric rating scale at 12 hours which is our primary outcome. We convert and calculate these numbers to mean from Luo et al. (2018) and standard deviation from Wan et al. (2014) and found a mean difference of 1.75 and standard deviation of 2.45 and 1.97 for the two study groups creating effect size of 0.78. Depending on a significance level (α) of 0.05, a power (1 - β) of 0.80, allocation ratio 1:1 and two-tailed, a sample size of 27 patients is required for each group. Due to the possibility of dropout rate and exclusion of some objects, the study will be planned to include 60 patients (30 patients in each group).

Statistical analysis will be conducted using IBM SPSS Statistics 22 (IBM Corp., Armonk, NY, USA). The normal distribution of data will be assessed by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Mean and standard deviation will be used as descriptive statistics for normally distributed numerical variables, while median and interquartile range (25th to 75th percentiles) will be used as descriptive statistics for non-normally distributed numerical variables. In addition, Chi-square test will be employed to test the significance between categorical variables. Independent t test will be employed for numerical data that exhibited normal distribution, whereas the Mann Whitney test will be used for numerical data that did not adhere to normal distribution. A significance level of p < 0.05 will be deemed to be statistically significant

Type d'étude

Interventionnel

Inscription (Réel)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Al Fayyum, Egypte, 63514
        • Fayoum university hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

50 ans à 90 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

ages from 50 to 90 years and undergoing bipolar hemiarthroplasty in Fayoum university hospital American Society of Anesthesiologists (ASA) physical status I to III,.

Exclusion Criteria:

Patient refusal. contraindication to spinal anesthesia . clinically significant coagulopathy. infection at the injection site. allergy to local anesthetics. body mass index>35 kg m2., diabetic or other neuropathies. patients receiving opioids for chronic analgesic therapy.

-

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: PENG block group

patients will receive PENG block after skin closure, .Patients will be placed in the supine position. The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle .

The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle

Comparateur actif: PAI group

PIA BLOCK For subjects randomized to PAI , LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. IT will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.

LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. It will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
the pain score (NRS)
Délai: at 12 hours after injection of local anethesia

the pain score (NRS) after surgery at rest (score 0 =no pain and 10 =worst pain ever) .

at 12 hours after injection of local anethesia

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
the pain score (NRS)
Délai: at 6, 18, 24, and 48 hours after injection of local anethesia

the pain score (NRS) after surgery at rest (score 0 =no pain and 10 =worst pain ever)

at 6, 18, 24, and 48 hours after injection of local anethesia
Incidence of quadriceps motor block
Délai: at 3,6,24 hours after injection of local anesthesia

paresis or paralysis of knee extension) at 3,6,24 hours postoperatively. Knee extension Will be evaluated in a supine position with the patient's hip and knee flexed at 45° and 90°, respectively. The patient will be asked to extend the knee first against gravity and then against resistance. Knee extension will be graded according to a 3-point scale: 0=normal strength (extension against gravity and against resistance); 1=paresis (extension against gravity but not against resistance); 2=paralysis (no extension possible

at 3,6,24 hours after injection of local anesthesia
cumulative morphine consumption in 24 hours.
Délai: at 24 hours after injection of local anethesia

net total doses of morphine used after surgery

at 24 hours after injection of local anethesia
The incidence of block-related adverse events (ie, vascular puncture, LA toxicity).
Délai: at 24 hours after injection of local anethesia

complication of injection of local anethesia (ie, vascular puncture, toxicity).

at 24 hours after injection of local anethesia

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Mohamed A Hamed, MD, Faculty of medicine, Fayoum university

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 novembre 2024

Achèvement primaire (Réel)

31 août 2025

Achèvement de l'étude (Réel)

31 octobre 2025

Dates d'inscription aux études

Première soumission

2 novembre 2024

Première soumission répondant aux critères de contrôle qualité

5 novembre 2024

Première publication (Réel)

6 novembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

26 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner